Orthogon Therapeutics announces a follow-up financing of USD 8 million to advance its leading BK virus drug – QNT Press Release


The company is developing the first oral antiviral drug to treat one of the most common viral infections in children and adult transplant patients

Orthogon Therapeutics LLC is a drug development company focused on designing innovative antiviral drugs and anti-infective therapies. The company announced that it has raised $8 million in funding from the leading consortium of Medical Angels in the United States to advance its first-class drug asset pipeline. This financing brings the company’s total investment to date to $12.5 million.

Dr. Ali H. Munawar, CEO of Orthogon Therapeutics and former founding CEO of Novira Therapeutics, said: “Orthogon is committed to advancing the first oral antiviral drug to treat BK virus infection. “Our mission is to develop a… A safe and effective prevention and treatment option.

The full story on Benzinga.com



Source link

Recommended For You

About the Author: News Center